-$0.32 EPS Expected for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Quarter
Equities analysts forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.43) to ($0.23). Lexicon Pharmaceuticals reported earnings of ($0.35) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The firm is expected to report its next quarterly earnings report on Tuesday, November 7th.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($1.46) per share for the current financial year, with EPS estimates ranging from ($1.55) to ($1.37). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.17) to ($0.58). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. The company had revenue of $12 million during the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. Lexicon Pharmaceuticals’s quarterly revenue was down 40.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.37) EPS.
Several equities research analysts recently commented on LXRX shares. HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $27.00.
Shares of Lexicon Pharmaceuticals (LXRX) traded up 0.76% during trading on Friday, hitting $14.62. 630,283 shares of the stock were exchanged. The stock has a 50-day moving average of $16.17 and a 200 day moving average of $15.41. Lexicon Pharmaceuticals has a 12-month low of $13.41 and a 12-month high of $19.62. The stock’s market cap is $1.54 billion.
A number of large investors have recently bought and sold shares of the company. USS Investment Management Ltd bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at $57,705,000. Norges Bank bought a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at $12,582,000. Pinnacle Associates Ltd. bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at $11,759,000. Vanguard Group Inc. raised its stake in Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares during the period. Finally, Highbridge Capital Management LLC bought a new stake in Lexicon Pharmaceuticals during the first quarter valued at $7,813,000.
TRADEMARK VIOLATION WARNING: “-$0.32 EPS Expected for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/13/0-32-eps-expected-for-lexicon-pharmaceuticals-inc-nasdaqlxrx-this-quarter.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.